STOCK TITAN

Enhabit SEC Filings

EHAB NYSE

Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Medicare reimbursement tables, patient-day metrics, and hospice turnover data are scattered across hundreds of pages of Enhabit’s disclosures. If parsing those figures in the latest Enhabit annual report 10-K simplified seems daunting, you’re not alone. Healthcare accounting rules create footnotes that read like another language. Stock Titan’s AI turns that language into clear insights, making Enhabit SEC filings explained simply. Whether you’re scanning for regulatory risks or auditing segment margins, our platform surfaces what matters before you wade through dense jargon.

Need the next Enhabit quarterly earnings report 10-Q filing or an alert on Enhabit Form 4 insider transactions real-time? Our engine pulls every document the moment it hits EDGAR and delivers AI-powered summaries in seconds. Investors searching for:

  • Enhabit insider trading Form 4 transactions
  • Enhabit proxy statement executive compensation
  • Enhabit 8-K material events explained
  • Enhabit earnings report filing analysis

receive a single dashboard that connects each form to real questions: What did executives buy, how did home-health margins shift, and did CMS rule changes impact revenue guidance?

Understanding Enhabit SEC documents with AI also means context. Our tools highlight hospice census trends, regional payor mixes, and quality-of-care metrics buried deep in footnotes. Curious about Enhabit executive stock transactions Form 4 ahead of a rate update? Want a red-lined comparison that shows how the new filing differs from last year? Stock Titan provides real-time updates, side-by-side comparisons, and plain-English explanations, so you can decide faster, act sooner, and focus on the fundamentals driving home-health performance.

Rhea-AI Summary

Insider activity reported: Tyler Technologies, Inc. (TYL) filed a Form 4 disclosing that Chief Operating Officer Jeffrey David Puckett acquired company stock on 06/30/2025.

  • Security: Common Stock
  • Shares acquired: 7.4417
  • Price paid: $503.914 per share
  • Transaction code: A (open-market/plan acquisition)
  • Plan: Purchase made through the Tyler Technologies, Inc. 2004 Employee Stock Purchase Plan
  • Post-transaction holding: 6,982.2057 shares held directly

No derivative securities were involved, and the filing was submitted by attorney-in-fact Randall G. Ray on 07/02/2025. The COO remains subject to Section 16 reporting requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit, Inc. (EHAB) – Form 4 insider transaction

Chief Human Resources Officer Tanya Renee Marion reported a single transaction dated 1 July 2025. Under transaction code F (shares withheld by the issuer to satisfy tax obligations upon vesting), 1,983 common shares were disposed of at an average price of $7.88 per share. Following the withholding, the executive’s direct beneficial ownership stands at 57,651 common shares. No derivative securities were reported, and the filing was signed on 2 July 2025.

The transaction represents routine tax-related share withholding rather than an open-market sale, so it does not materially alter the insider’s economic exposure or signal a change in conviction. The filing meets Section 16 reporting requirements and contains no additional commentary or unusual provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ConocoPhillips (COP) Form 4 filing dated 07/02/2025 discloses that director Kathleen A. McGinty acquired 1,212 deferred stock units on 07/01/2025. The units were granted at an accounting value of $90.765 per unit and convert to common shares on a 1-for-1 basis. Following the grant, McGinty beneficially owns 1,212 derivative securities, all held directly.

The award is classified under transaction code “A,” indicating a grant rather than an open-market purchase. According to the accompanying footnote, the director has elected to receive the shares as a lump-sum six months after leaving the board, although she may revise this distribution schedule. No non-derivative share transactions were reported, and no disposals occurred.

While the transaction aligns the director’s compensation with shareholder value, the dollar value of the grant (~$110,000) is modest relative to ConocoPhillips’ multi-billion-dollar market capitalization and therefore unlikely to have a material impact on valuation. Nevertheless, insider acquisitions—even via equity grants—can be viewed positively by investors who value board-level ownership incentives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

UBS AG is offering Step Down Trigger Autocallable Notes (unsubordinated, unsecured debt) maturing 5 July 2030 that are linked to the least-performing of three underlying assets: 1) Nasdaq-100 Technology Sector Index (NDXT), 2) Russell 2000 Index (RTY) and 3) Energy Select Sector SPDR Fund (XLE). The notes are issued in $1,000 denominations (aggregate offering $100,000) and priced at par, but their estimated initial value is $982.50, reflecting embedded fees and hedging costs.

Automatic call mechanism. Beginning 12 months after settlement, UBS will observe the underlying assets quarterly. If the closing level of each asset is at or above its step-down call threshold, the note is automatically called and the investor receives the call price (principal plus a call return). Call thresholds start at 100 % of initial levels and fall to 70 % by the final valuation date. The call return rate is 12.5 % per annum, rising from 12.5 % (after year 1) to 62.5 % (if called at maturity).

Downside exposure. If the notes are not called and at least one asset finishes < 70 % of its initial level, investors suffer a loss equal to the decline in the worst-performing asset; in a severe draw-down they could lose their entire principal. No interest is paid and investors forgo dividends on XLE.

Credit & liquidity. Payments depend on UBS’s credit; the notes are not FDIC-insured. They will not be listed, and secondary-market liquidity is uncertain. UBS Securities LLC will receive a $2.50 underwriting discount per note and may temporarily quote above model value, but bid–ask spreads can widen after launch.

  • Trade date: 30 Jun 2025; Settlement: 3 Jul 2025
  • Final valuation date: 30 Jun 2030; Maturity: 5 Jul 2030
  • Downside thresholds: NDXT 8,149.34; RTY 1,522.525; XLE $59.37 (all 70 % of initial levels)
  • Maximum call price: $1,625 (62.5 % total return) if all assets ≥ 70 % on final date

Risk considerations. Investors face concentrated exposures to technology, small-cap and energy sectors, correlation risk (all three assets must meet thresholds), full downside to worst asset, and potential Swiss resolution measures affecting UBS debt. The product best suits investors who fully understand structured-note mechanics, can tolerate principal loss, and anticipate at least moderate stability or growth across all three reference assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit, Inc. (EHAB) – Form 4 insider transaction

Director Barry P. Schochet bought 15,773 shares of Enhabit common stock on 26 June 2025 at a reported price of $9.51 per share. Following the purchase, Schochet’s direct holding rose to 61,614 shares. No derivative securities were involved, and no dispositions were reported.

This acquisition increases the director’s stake by roughly 34% (15,773 ÷ 45,841 previously held) and may be interpreted by investors as a vote of confidence in the company’s prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) director Gregory S. Rush filed a Form 4 disclosing the open-market purchase of 15,773 common shares at $9.51 on 26 Jun 2025. After the trade, Rush directly owns 69,479 shares of EHAB.

No derivative positions or additional transactions were reported in this routine insider filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Mark W. Ohlendorf purchased 15,773 shares of common stock on 26-Jun-2025 at an average price of $9.51.

The acquisition lifts the director’s direct holdings to 37,723 shares, representing a roughly 72 % increase in his stake. No dispositions, derivative securities, or Rule 10b5-1 trading-plan indications were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 on 28 June 2025 reporting that director Stuart M. McGuigan acquired 15,773 common shares on 26 June 2025 at $9.51 per share. The open-market purchase, coded "A" for acquisition, raises his direct beneficial ownership to 67,322 shares, a ~23% increase versus his prior holding. No derivative securities or additional insiders were disclosed, and the filing does not reference a Rule 10b5-1 trading plan. Aside from this single transaction, the statement contains no other material events, financial data, or explanatory footnotes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 reporting that director Erin Hoeflinger acquired 15,773 shares of common stock on 06/26/2025 at $9.51 per share. The transaction, coded “A” (acquisition), is valued at roughly $150 thousand. Following the purchase, Hoeflinger’s direct ownership stands at 70,089 shares. No derivative securities or additional transactions were disclosed in the filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Enhabit, Inc. (EHAB) Form 4 filing – insider purchase

Director Charles M. Elson reported an open-market acquisition of 15,773 common shares on 06/26/2025 at $9.51 per share (Transaction Code "A"). After the transaction, his direct beneficial ownership stands at 72,494 shares. No derivative security trades or dispositions were disclosed, and there is no indication the trade was executed under a Rule 10b5-1 plan.

The purchase increases the director’s equity exposure and can be viewed as a personal vote of confidence in Enhabit’s outlook. No other material events or financial metrics were included in the filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Enhabit (EHAB)?

The current stock price of Enhabit (EHAB) is $7.65 as of July 3, 2025.

What is the market cap of Enhabit (EHAB)?

The market cap of Enhabit (EHAB) is approximately 481.6M.

What services does Enhabit Inc provide?

Enhabit Inc offers comprehensive home health and hospice care services. Their home health services include skilled nursing, therapy, and supportive care, while the hospice segment focuses on symptom management and quality of life for patients with advanced illnesses.

How is Enhabit Inc structured in terms of service segments?

The company operates through two major segments: home health and hospice. The home health segment deals with Medicare-certified nursing and therapy services, whereas the hospice segment provides care focused on patient comfort during life-limiting illnesses.

How does Enhabit generate its revenue?

Enhabit generates most of its revenue from its home health division, offering a broad range of services under Medicare guidelines. The hospice services complement their operations, emphasizing patient-centered care without relying on direct product sales.

What distinguishes Enhabit in the competitive healthcare market?

Enhabit differentiates itself by integrating advanced technologies with expert clinical care in a home-based setting. Its dual focus on home health and hospice care allows for a broader service offer compared to competitors focusing on a single care model.

How does Enhabit ensure the quality of its patient care?

Quality is maintained through a blend of experienced clinical teams, adherence to Medicare guidelines, and the use of advanced health technology. This approach ensures that care is patient-focused, efficient, and tailored to meet individual health needs.

In what ways does Enhabit incorporate technology into its services?

The company integrates innovative technology for scheduling, patient monitoring, and data management. This technological approach enhances operational efficiency and supports clinical decision-making, ensuring quality care delivery in a home setting.

What role does Enhabit play in the US healthcare landscape?

Enhabit serves as a key provider of home health and hospice care, addressing the growing demand for patient-centered services in the comfort of patients' homes. Its focus on both acute rehabilitation and palliative care positions it uniquely within the healthcare ecosystem.

How do Enhabit’s services support the needs of patients and their families?

Enhabit’s services are designed to align with patient preferences by offering care at home, reducing the stress of institutional settings. Their holistic approach not only addresses clinical needs but also provides emotional and social support for both patients and their families.
Enhabit

NYSE:EHAB

EHAB Rankings

EHAB Stock Data

481.56M
49.02M
3.23%
102.53%
2.54%
Medical Care Facilities
Services-home Health Care Services
Link
United States
DALLAS